Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from VolitionRX ( (VNRX) ).
On October 10, 2025, VolitionRx Limited entered into an Underwriting Agreement with Newbridge Securities Corporation for a public offering of 11,550,000 shares of common stock, along with warrants for an equal number of shares. The offering was priced at $0.52 per share, including a $0.01 warrant, with a 7% underwriting discount. On November 7, 2025, an amendment to the agreement allowed the underwriter to exercise an over-allotment option for 1,194,000 shares and 1,732,500 warrants at the same price, enhancing flexibility in the offering.
The most recent analyst rating on (VNRX) stock is a Sell with a $0.50 price target. To see the full list of analyst forecasts on VolitionRX stock, see the VNRX Stock Forecast page.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Underperform.
VolitionRX’s overall stock score is primarily impacted by its weak financial performance and bearish technical indicators. The company’s financial instability, negative equity, and cash burn issues are significant concerns. While there are positive developments in cost reduction and revenue growth, these are overshadowed by the lack of profitability and uncertain revenue projections.
To see Spark’s full report on VNRX stock, click here.
More about VolitionRX
VolitionRx Limited operates in the biotechnology industry, focusing on developing blood-based diagnostic tests for detecting and diagnosing various diseases, with a particular emphasis on cancer.
Average Trading Volume: 533,060
Technical Sentiment Signal: Sell
Current Market Cap: $51.36M
See more insights into VNRX stock on TipRanks’ Stock Analysis page.